The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

694

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

September 30, 2014

Conditions
Locally Advanced Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Fulvestrant

intramuscular injection

DRUG

Exemestane

oral capsule

Trial Locations (117)

Unknown

Research Site, Birmingham

Research Site, Arcadia

Research Site, Fountain Valley

Research Site, Laverne

Research Site, Long Beach

Research Site, Santa Rosa

Research Site, Torrington

Research Site, Washington D.C.

Research Site, Boca Raton

Research Site, Gainesville

Research Site, Jacksonville

Research Site, Miami

Research Site, New Port Richey

Research Site, Pensacola

Research Site, Athens

Research Site, Chicago

Research Site, Harvey

Research Site, Springfield

Research Site, Iowa City

Research Site, Overland Park

Research Site, Baton Rouge

Research Site, Metairie

Research Site, New Orleans

Research Site, Shreveport

Research Site, Bangor

Research Site, Baltimore

Research Site, Frederick

Research Site, Kalamazoo

Research Site, Royal Oak

Research Site, Saint Joseph

Research Site, Hooksett

Research Site, Livingston

Research Site, Voorhees Township

Research Site, Albuquerque

Research Site, Charlotte

Research Site, Durham

Research Site, Canton

Research Site, Hershey

Research Site, Lancaster

Research Site, Langhorne

Research Site, Pittsburgh

Research Site, Providence

Research Site, Columbia

Research Site, Greenville

Research Site, Spartenburg

Research Site, Austin

Research Site, Dallas

Research Site, Houston

Research Site, San Antonio

Research Site, Burlington

Research Site, Richmond

Research Site, Buenos Aires

Research Site, Ciudad de Buenos Aires

Research Site, Mar del Plata

Research Site, Rosario

Research Site, Brussels

Research Site, Leuven

Research Site, Ottignies

Research Site, Wilrijk

Research Site, Goiânia

Research Site, Rio de Janeiro

Research Site, Porto Alegre

Research Site, São Paulo

Research Site, Edmonton

Research Site, Penticton

Research Site, Vancouver

Research Site, Winnipeg

Research Site, St. John's

Research Site, Kingston

Research Site, London

Research Site, Newmarket

Research Site, Oshawa

Research Site, Ottawa

Research Site, Sault Ste. Marie

Research Site, Toronto

Research Site, Windsor

Research Site, Montreal

Research Site, Québec

Research Site, Aalborg

Research Site, Herning

Research Site, Hillerød

Research Site, København Ø

Research Site, Roskilde

Research Site, Sønderborg

Research Site, Bordeaux

Research Site, Lille

Research Site, Montpellier

Research Site, Vandœuvre-lès-Nancy

Research Site, Augsburg

Research Site, Berlin

Research Site, Hamburg

Research Site, Regensburg

Research Site, Budapest

Research Site, Debrecen

Research Site, Szeged

Research Site, Haifa

Research Site, Tel Aviv

Research Site, Obninsk

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Klerksdorp

Research Site, Bloemfontein

Research Site, Cape Town

Research Site, Johannesburg

Research Site, Port Elizabeth

Research Site, Pretoria

Research Site, Seville

Research Site, Barcelona

Research Site, Hospitalet Dellobregat(barcelo

Research Site, Terrassa(barcelona)

Research Site, Madrid

Research Site, Valencia

Research Site, Halmstad

Research Site, Lund

Research Site, Stockholm

Research Site, Uppsala

Research Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00065325 - The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter